Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation

Vaccine

Volumn 23, Issue 16, 2005, Pages 1923-1930

  Moschos, Sterghios A ^a   Bramwell, Vincent W ^a   Somavarapu, Satyanarayna ^a   Alpar, H Oya ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adjuvant synergy; Chitosan; MDP; NOD; PAMP; TLR

Indexed keywords

CHITOSAN DERIVATIVE; HELICOBACTER PYLORI VACCINE; MURAMYL DIPEPTIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; FEMALE; HELICOBACTER INFECTION; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; UPREGULATION;

EID: 14244264350     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.10.016     Document Type: Article

References (51)

1. H.O. Alpar Strategies for vaccine delivery-Preface J Drug Target 11 2003 459 461
2. R. Ghirardelli, F. Bonasoro, C. Porta, and D. Cremaschi Identification of particular epithelial areas and cells that transport polypeptide-coated nanoparticles in the nasal respiratory mucosa of the rabbit Biochim et Biophys Acta 1416 1-2 1999 39 47
3. J.E. Eyles, V.W. Bramwell, E.D. Williamson, and H.O. Alpar Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration Vaccine 19 2001 4732 4742
4. S.M. Kang, Q. Yao, L. Guo, and R.W. Compans Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B J Virol 77 18 2003 9823 9830
5. I.D. Spiers, H.O. Alpar, J.E. Eyles, A. Bozkir, J. Miller, and ED. Williamson Studies on the co-encapsulation, release and integrity of two subunit antigens: rV and rF1 from Yersinia pestis J Pharm Pharmacol 51 9 1999 991 997
6. L. Vidard, M. Kovacsovics-Bankowski, S. Kraeft, L.B. Chen, B. Benacerraf, and K.L. Rock Analysis of MHC class II presentation of particulate antigens by B lymphocytes J Immonol 156 1996 2809 2818
7. S. Peppoloni, P. Ruggiero, M. Contorni, M. Morandi, M. Pizza, and R. Rappuoli Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines Exp Rev Vaccines 2 2003 285 293
8. A. Nohria, and R.H. Rubin Cytokines as potential vaccine adjuvants Biotherapy 7 3-4 1994 261 269
9. F. Heil, H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, and S. Akira Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 Science 303 5663 2004 1526 1529
10. K. Hoebe, E.M. Janssen, S.O. Kim, L. Alexopoulou, R.A. Flavell, and J. Han Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways Nature Immunol 4 2003 1223 1229
11. M. Yamamoto, S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, and H. Sanjo Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway Science 301 2003 640
12. H.O. Alpar, J.E. Eyles, E.D. Williamson, and S. Somavarapu Intranasal vaccination against plague, tetanus and diphtheria Adv Drug Deliv Rev 51 1-3 2001 173 201
13. K.F. Griffin, J.E. Eyles, I.D. Spiers, H.O. Alpar, and ED. Williamson Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-γ or IL-4, but not IL-6 Vaccine 20 31-32 2002 3650 3657
14. L. Faulkner, G. Buchan, L. Slobbe, E. Lockhart, J. Wales, and M. Wilson Influenza hemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection Vaccine 21 9-10 2003 932 939
15. K. Fearon, J.D. Marshall, C. Abbate, S. Subramanian, P. Yee, and J. Gregorio A minimal human immunostimulatory CpG motif that potently induces IFN-γ and IFN-α production Euro J Immunol 33 8 2003 2114 2122
16. A. Allison Squalene and squalane emulsions as adjuvants Methods 19 1999 87 93
17. M. Zunic, F. Kricek, P. Dukor, and G.M. Bahr Oral administration of muramyl dipeptide into mice modulates cell proliferation, immunoglobulin synthesis, and cytokine mRNA levels in gut associated lymphoid tissues Int J Immunopharmacol 18 1996 155 162
18. A. Fukushima, Y.C. Yoo, K. Yoshimatsu, K. Matsuzawa, M. Tamura, and S. Tono-oka Effect of MDP-Lys (L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus Vaccine 14 1996 485 491
19. J.E. Eyles, V.W. Bramwell, J. Singh, E.D. Williamson, and H.O. Alpar Stimulation of spleen cells in vitro by nanospheric particles containing antigen J Controll Release 86 1 2003 25 32
20. S. Moschos, S. Somavarapu, J. Singh, V. Bramwell, L. Randall, and B. Guy Immunogenicity of adjuvanted recombinant urease administered intranasally Proceedings of the International Symposium for the Controlled Release of Bioactive Materials 28 2001 1111 1112
21. R. Weltzin, B. Guy, W.D. Thomas Jr., P.J. Giannasca, and T.P. Monath Parenteral adjuvant activities of E. coli heat-labile toxin and its B subunit for immunization of mice against gastric H. pylori infection Infect Immun 68 5 2000 2775 2782
22. A.P. Gobert, B.D. Mersey, Y. Cheng, D.R. Blumberg, J.C. Newton, and K.T. Wilson Cutting edge: urease release by H. pylori stimulates macrophage inducible nitric oxide synthase J Immunol 168 12 2002 6002 6006
23. X. Fan, H. Gunasena, Z. Cheng, R. Espejo, S.E. Crowe, and P.B. Ernst H. pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis J Immunol 165 4 2000 1918 1924
24. K. Fujihashi, T. Koga, F.W. van Ginkel, Y. Hagiwara, and J.R. McGhee A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants Vaccine 20 2002 2431 2438
25. N. Inohara, and G. Nuñez NODs: intracellular proteins involved in inflammation and apoptosis Nature Rev Immunol 3 2003 371 382
26. R. Jagus, B. Joshi, and G.N. Barber PKR apoptosis and cancer Int J Biochem Cell Biol 31 1999 123 138
27. O. Takeuchi, and S. Akira MyD88 as a bottle neck in Toll/IL-1 signalling Curr Topics Microbiol Immunol 270 2002 155
28. A. Biragyn, P.A. Ruffini, C.A. Leifer, E. Klyushnenkova, A. Shakhov, and O. Chertov Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2 Science 298 5595 2002 1025 1029
29. C. Garlanda, F. Riva, N. Polentarutti, C. Buracchi, M. Sironi, and M. De Bortoli Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family Proceedings of the National Academy of Sciences of the United States of America 101 10 2004 3522 3526
30. S. Gunnery, and M.B. Mathews RNA binding and modulation of PKR activity Methods: A Compan Methods Enzymol 15 1998 189 198
31. R. Cai, B. Carpick, R.F. Chun, K.T. Jeang, and B.R. Williams HIV-I TAT inhibits PKR activity by both RNA-dependent and RNA-independent mechanisms Arch Biochem Biophys 373 2 2000 361 367
32. A.E. Gelman, J. Zhang, Y. Choi, and L.A. Turka Toll-like receptor ligands directly promote activated CD4(+) T cell survival J Immunol 172 10 2004 6065 6073
33. G. Ott, G.L. Barchfeld, and G. Van Nest Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59 Vaccine 13 1995 1557 1562
34. M.C. Keefer, M. Wolff, G.J. Gorse, B.S. Graham, L. Corey, and M.L. Clements-Mann Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group AIDS Res Human Retroviruses 13 1997 1163 1177
35. B.S. Graham, M.C. Keefer, M.J. McElrath, G.J. Gorse, D.H. Schwartz, and K. Weinhold Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial NIAID AIDS Vaccine Evaluation Group Annal Internal Med 125 1996 270 279
36. P.D. Becker, R.S. Corral, C.A. Guzman, and S. Grinstein Adamantylamide dipeptide as effective immunoadjuvant in rabbits and mice Vaccine 19 2001 4603 4609
37. D.J. Fast, and G.J. Vosika The muramyl dipeptide analog GMTP-N-MDP preferentially induces cellular immunity to soluble antigens Vaccine 15 1997 1748 1752
38. M.T. Whary, L.S. Palley, M. Batchelder, J.C. Murphy, L. Yan, and N.S. Taylor Promotion of ulcerative duodenitis in young ferrets by oral immunization with Helicobacter mustelae and muramyl dipeptide Helicobacter 2 1997 65 77
39. Y.C. Yoo, K. Yoshimatsu, Y. Koike, R. Hatsuse, K. Yamanishi, and O. Tanishita Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine Vaccine 16 1998 216 224
40. S. Gobec, M. Sollner-Dolenc, U. Urleb, B. Wraber, S. Simcic, and M. Filipic Modulation of cytokine production by some phthalimido-desmuramyl dipeptides and their cytotoxicity Farmaco 59 5 2004 345 352
41. N. Inohara, Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons, and J. Crespo Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease J Biol Chem 278 2003 5509 5512
42. P. Artursson, T. Lindmark, S.S. Davis, and L. Illum Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2) Pharm Res 11 1999 1358 1361
43. A.F. Kotze, M.M. Thanou, and H.L. Luessen De Boer AG, Verhoef JC, Junginger HE. Enhancement of paracellular drug transport with highly quaternized N-trimethyl chitosan chloride in neutral environments: In vitro evaluation in intestinal epithelial (cells Caco-2) J Pharm Sci 88 1999 253 257
44. M.M. Thanou, A.F. Kotze, T. Scharringhausen, H.L. Luessen, A.G. de Boer, and J.C. Verhoef Effect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal Caco-2 cell monolayers J Controll Release 64 2000 15 25
45. R.J. Soane, M. Frier, A.C. Perkins, N.S. Jones, S.S. Davis, and L. Illum Evaluation of the clearance characteristics of bioadhesive systems in humans Int J Pharm 178 1999 55 65
46. R.J. Soane, M. Hinchcliffe, S.S. Davis, and L. Illum Clearance characteristics of chitosan based formulations in the sheep nasal cavity Int J Pharm 217 2001 183 191
47. J. Brooking, S.S. Davis, and L. Illum Transport of nanoparticles across the rat nasal mucosa J Drug Target 9 2001 267 279
48. S.S. Davis, and L. Illum Absorption enhancers for nasal drug delivery Clin Pharmacokinet 42 2003 1107 1128
49. Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Giudice GD. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine. 2003;21(25-26):3837-44.
50. T. Tanahashi, M. Kita, T. Kodama, Y. Yamaoka, N. Sawai, and T. Ohno Cytokine expression and production by purified H. pylori urease in human gastric epithelial cells Infect Immun 68 2000 664 671
51. Bacon A, Makin J, Sizer PJ, Jabbal-Gill, I, Hinchcliffe, M, Illum L. et al., Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infec Immun 68:5764-70.